Close Menu

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific said today that it will collaborate with the Newman-Lakka Institute for Personalized Cancer Care at Floating Hospital for Children at Tufts Medical Center on methods for detecting and tracking blood-based protein biomarkers for various cancers.

The work will focus on applying the company's liquid chromatography-mass spectrometry equipment along with its mass spectrometry immunoassay technology to identify markers for breast and prostate cancer as well as tumor-associated blood vessel formation.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.

The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.

A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.

In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.

Mar
31
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.